L-dopa is combined with carbidopa in the treatment of parkinsonism to
**Core Concept**
The combination of L-dopa and carbidopa is based on the principle of inhibiting the peripheral conversion of L-dopa to dopamine, thereby increasing its availability in the central nervous system. This is crucial for the treatment of **parkinsonism**, a neurological disorder characterized by **dopamine deficiency**.
**Why the Correct Answer is Right**
Carbidopa inhibits the enzyme **dopamine decarboxylase**, which is responsible for the conversion of L-dopa to dopamine outside the brain, thus preventing the peripheral formation of dopamine and allowing more L-dopa to cross the **blood-brain barrier**. This increases the amount of L-dopa available for conversion to dopamine in the brain, enhancing its therapeutic effect.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because while carbidopa does inhibit an enzyme, the primary goal is not to reduce side effects but to increase the bioavailability of L-dopa in the brain.
**Option B:** Incorrect as carbidopa's role is not to directly act on dopamine receptors.
**Option C:** Incorrect because carbidopa does not directly increase dopamine levels but rather prevents its premature conversion outside the brain.
**Option D:** Incorrect as the combination is not primarily for reducing the dose of L-dopa required.
**Clinical Pearl / High-Yield Fact**
A key point to remember is that carbidopa has no therapeutic effect on parkinsonism when used alone, highlighting its role as an adjunct to L-dopa therapy.
**Correct Answer:** D. to increase the availability of L-dopa in the central nervous system by preventing its peripheral conversion to dopamine.